GAMIFANT
PeakmAbemapalumab-lzsg
BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
GAMIFANT (emapalumab-lzsg) is interferon gamma antagonists [moa]. First approved in 2018.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GAMIFANT (emapalumab-lzsg) is a monoclonal antibody that blocks interferon gamma, a key cytokine driving excessive immune activation. It is indicated for primary hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening hyperinflammatory disorder. The drug works by antagonizing IFN-γ signaling to reduce pathologic immune activation and restore immune homeostasis.
$0.983MPart D
PeakProduct is at peak commercial maturity with modest Part D utilization reflecting the ultra-rare indication; team focus is on optimizing access and maintaining specialist awareness.
Mechanism of Action
Interferon gamma Antagonists
Pharmacologic Class:
Interferon gamma Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GAMIFANT offers rare-disease expertise in a highly specialized immunology niche with strong brand loyalty and limited competitive distractions. However, the ultra-narrow patient population and modest claims volume mean the team is lean and success depends on physician education, care-center partnerships, and expansion into secondary indications.
Brand Manager — Orphan/Rare Disease
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.